Research, Charts & Company Announcements
Research Tree provides access to ongoing research coverage, media content and regulatory news on LLOYD FONDS AG. We currently have 2 research reports from 1 professional analysts.
Frequency of research reports
Research reports on
LLOYD FONDS AG
LLOYD FONDS AG
A few positives in the January 2017 renewals
03 Jan 17
The January reinsurance renewals were broadly as expected, with some small positives as rate reductions moderated (but still fell YoY). US reinsurance rates should bottom out this year but negative pressures will continue affect PBT in 2017. We expect luck to play a greater role in claims activity reported. Without a major catalyst, the ample capacity still available suggests prices could bump along the bottom for some time. It’s an unexciting story – but the Lloyd’s insurers offer some protection given their broader books of business.
Non-Life Insurance - US Flood exposure – demand rising
11 Oct 16
US flood is a costlier risk than is often recognised as much of the exposure is taken by the federally-guaranteed National Flood Insurance Program (NFIP). However, the rising cost of flood losses means US Congress has proposed to offer a choice between the NFIP and the private insurance market – the expected flood losses from Hurricane Matthew may focus attention further. This could provide an interesting growth opportunity for (re)insurers in the Excess & Surplus Lines market (where Lloyd’s is currently the No1 player).
Another positive verdict
20 Mar 17
Burford’s results for 2016 produced another outstanding set of figures. Revenue grew by 60% to $163.4m with strong growth in the litigation finance business and an additional boost from a secondary sale in the Petersen case. On an underlying basis net income grew to $114m, a 75% increase despite the investment in growing capacity which increased costs. A combination of ongoing investment and gains and increases on valuation saw the fair value of the litigation assets increase 67% to $559m, underpinned by a growth in invested capital to $394m. With the results statement there was an announcement of a further sale of 9% of the Petersen case at a valuation of 20 times the cost of investment.
N+1 Singer - Morning Song 22-03-2017
22 Mar 17
Carador Income Fund (CIFU LN) Premium rating restored, high levels of refinancing activity | Cello Group (CLL LN) Outlook getting brighter – watch Pulsar | Eckoh (ECK LN) Largest ever US secure payments win | eg solutions (EGS LN) Full year results in line | Futura Medical (FUM LN) Licensing deal for CSD500 in Portugal | Verona Pharma (VRP LN) Global agreement with QuintilesIMS to support development of RPL554 | Xaar (XAR LN) 2016 results slightly ahead, reduced visibility in 2017
Small Cap Breakfast
21 Mar 17
First Sentinel—Investment company expecting NEX admission/introduction on 24 March. £636k raised pre-IPO. BioPharma Credit—Expected Gross Initial Acquisition Proceeds now c.$338m. Gross Cash Proceeds capped at $423m with placing and open offer. Results expected 23 March with admission now due 30 march. Tufton Oceanic Assets- The Company intends to invest in a diversified portfolio of second hand commercial sea-going vessels where the Investment Manager believes that an attractive opportunity exists in shipping. $150m raise. Admission 3 April.